{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:03:44Z","timestamp":1794747824301,"version":"4.9.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>A significant proportion of patients with large B-cell lymphoma (LBCL) experience relapsed or refractory (R\/R) disease after first-line (1L) therapy. Chimeric antigen receptor T-cell (CAR T) therapy is approved for R\/R LBCL, yet real-world use remains unclear. This retrospective study evaluated treatment patterns and survival outcomes in patients potentially eligible for CAR T in the Flatiron Health Research Database. Patients diagnosed with LBCL from 2011 to 2024 who initiated 1L therapy were assessed. Predictors of mortality before the opportunity to initiate second-line (2L) therapy were evaluated using competing risk regression models. Treatment patterns among subgroups that initiated 2L and third-line (3L) therapy based timing of US Food and Drug Administration indication approvals for CAR T were evaluated and stratified by CAR T fitness using age and Eastern Cooperative Oncology Group performance status (ECOG PS) score. Among 10\u2009016 patients who initiated 1L therapy, 13% died within 1 year without initiating 2L therapy, and 30% initiated 2L therapy. In competing risk analyses, 11% of patients with an ECOG PS score of 0\/1\/unknown (combined) died within 12 months of initiating 1L therapy before being able to receive 2L therapy. Among patients deemed eligible and fit for CAR T therapy, 25% received 2L CAR T therapy, and 36% received 3L CAR T therapy. Despite its curative potential, CAR T uptake remains low in potentially eligible patients, with many dying within 1 year of initiating 1L therapy and before the opportunity to receive CAR Ts. Early collaboration between the community oncologist and CAR T center, improved access, and expanded patient awareness strategies are needed to improve CAR T therapy uptake.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019064","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:53:41Z","timestamp":1780516421000},"page":"5325-5337","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Real-world treatment patterns of patients with large B-cell lymphoma over time and into a post\u2013CAR T approval era"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"3The University of Kansas Cancer Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Fesen","sequence":"additional","affiliation":[{"name":"4Central Care Cancer Center, Great Bend, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Snider","sequence":"additional","affiliation":[{"name":"5Flatiron Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4251-2912","authenticated-orcid":false,"given":"Blythe","family":"Adamson","sequence":"additional","affiliation":[{"name":"5Flatiron Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Proli","sequence":"additional","affiliation":[{"name":"5Flatiron Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hil","family":"Hsu","sequence":"additional","affiliation":[{"name":"6Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatunde","family":"Adedokun","sequence":"additional","affiliation":[{"name":"6Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik R.","family":"Patel","sequence":"additional","affiliation":[{"name":"6Kite, a Gilead company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"6","key":"2026081110264187000_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"A Cancer J Clin"},{"issue":"16","key":"2026081110264187000_bib2","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2026081110264187000_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"2026081110264187000_bib4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"2026081110264187000_bib5","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.1016\/j.blre.2019.100640","article-title":"Modern management of relapsed and refractory aggressive B-cell lymphoma: a perspective on the current treatment landscape and patient selection for CAR T-cell therapy","volume":"40","author":"Bachanova","year":"2020","journal-title":"Blood Rev"},{"issue":"7","key":"2026081110264187000_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"2026081110264187000_bib7","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"21","key":"2026081110264187000_bib8","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2026081110264187000_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36401\/JIPO-21-2","article-title":"Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?","volume":"4","author":"Tang","year":"2021","journal-title":"J Immunother Precis Oncol"},{"issue":"30","key":"2026081110264187000_bib10","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026081110264187000_bib11","unstructured":"Network NCC\n          . NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) B-cell lymphomas version 3.2024. Accessed 10 October 2024. https:\/\/www.nccn.org."},{"issue":"suppl 1","key":"2026081110264187000_bib12","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2021-151807","article-title":"CAR T therapy referral for diffuse large B cell lymphoma (DLBCL) by U.S. community hematology\/oncology (cH\/O) practices: perceptions and patterns","volume":"138","author":"Porter","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026081110264187000_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of community hematologists\/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"issue":"7","key":"2026081110264187000_bib14","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/j.jval.2022.04.1045","article-title":"HSD44 community hematologist\/oncologist (CH\/O) barriers to CAR T referral and concerns with possible in-office CAR-T administration","volume":"25","author":"Pink","year":"2022","journal-title":"Value Heal"},{"issue":"18","key":"2026081110264187000_bib15","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","article-title":"Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER-medicare data analysis","volume":"9","author":"Chung","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026081110264187000_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jamaoncol.2025.1127","article-title":"Barriers to chimeric antigen receptor T-cell therapy","volume":"11","author":"Valtis","year":"2025","journal-title":"JAMA Oncol"},{"issue":"12","key":"2026081110264187000_bib17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026081110264187000_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2024014171","article-title":"Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network","volume":"9","author":"Battiwalla","year":"2025","journal-title":"Blood Adv"},{"key":"2026081110264187000_bib19","doi-asserted-by":"crossref","first-page":"1481950","DOI":"10.3389\/fonc.2024.1481950","article-title":"Cellular therapy in older adults with relapsed\/refractory diffuse large B-cell lymphoma","volume":"14","author":"Esteghamat","year":"2024","journal-title":"Front Oncol"},{"issue":"10","key":"2026081110264187000_bib20","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-22-3136","article-title":"Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed\/refractory large B-cell lymphoma","volume":"29","author":"Westin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026081110264187000_bib21","author":"Flatiron Health","year":"2025"},{"issue":"suppl 1","key":"2026081110264187000_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene Ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"key":"2026081110264187000_bib23","unstructured":"US Food and Drug Administration\n          . FDA Approves CAR-T Cell Therapy to Treat Adults With Certain Types of Large B-Cell Lymphoma. Accessed 30 April 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma."},{"issue":"3","key":"2026081110264187000_bib25","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of $K$-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"8","key":"2026081110264187000_bib26","first-page":"703","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Control"},{"issue":"5","key":"2026081110264187000_bib27","doi-asserted-by":"crossref","first-page":"pkad058","DOI":"10.1093\/jncics\/pkad058","article-title":"Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022","volume":"7","author":"Guadamuz","year":"2023","journal-title":"JNCI Cancer Spectr"},{"issue":"4","key":"2026081110264187000_bib28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026081110264187000_bib29","doi-asserted-by":"crossref","first-page":"e7173","DOI":"10.1002\/cam4.7173","article-title":"Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy","volume":"13","author":"Sineshaw","year":"2024","journal-title":"Cancer Med"},{"issue":"16_suppl","key":"2026081110264187000_bib30","doi-asserted-by":"crossref","first-page":"TPS7578","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7578","article-title":"ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026081110264187000_bib31","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2026081110264187000_bib32","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2217\/fon-2018-0596","article-title":"Effects of center type and socioeconomic factors on early mortality and overall survival of diffuse large B-cell lymphoma","volume":"15","author":"Dhakal","year":"2019","journal-title":"Futur Oncol"},{"issue":"3","key":"2026081110264187000_bib33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cncr.23567","article-title":"The impact of socioeconomic status on survival after cancer in the United States","volume":"113","author":"Byers","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2026081110264187000_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/annonc\/mdj007","article-title":"Origins of socio-economic inequalities in cancer survival: a review","volume":"17","author":"Woods","year":"2006","journal-title":"Ann Oncol"},{"issue":"14","key":"2026081110264187000_bib35","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2026081110264187000_bib36","first-page":"546","article-title":"Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"28","author":"Perales","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"2026081110264187000_bib37","doi-asserted-by":"crossref","first-page":"e46721","DOI":"10.2196\/46721","article-title":"Use of digital health technology among older adults with cancer in the United States: findings from a National Longitudinal Cohort study (2015-2021)","volume":"25","author":"Zhou","year":"2023","journal-title":"J Med Internet Res"},{"key":"2026081110264187000_bib38","unstructured":"US Food and Drug Administration\n          . FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T Cell Immunotherapies. Accessed 8 October 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor."},{"issue":"7","key":"2026081110264187000_bib39","first-page":"358","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2026081110264187000_bib40","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/bloodadvances.2023011996","article-title":"Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy","volume":"8","author":"Karmali","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026081110264187000_bib41","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1182\/blood-2023-189084","article-title":"Impact of time from referral to treatment on outcomes and cost of therapy for patients undergoing chimeric antigen receptor T-cell therapy for B-cell lymphoma: an intention to treat analysis","volume":"142","author":"Patel","year":"2023","journal-title":"Blood"},{"key":"2026081110264187000_bib42","doi-asserted-by":"crossref","first-page":"1121030","DOI":"10.3389\/fimmu.2023.1121030","article-title":"Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells","volume":"14","author":"Hiltensperger","year":"2023","journal-title":"Front Immunol"},{"key":"2026081110264187000_bib43","doi-asserted-by":"crossref","first-page":"101358","DOI":"10.1016\/j.blre.2025.101358","article-title":"CAR-T for all? Barriers, facilitators, and interventions to commercial CAR T-cell therapy access","volume":"76","author":"Kaparis","year":"2026","journal-title":"Blood Rev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5325\/2536109\/blooda_adv-2025-019064-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5325\/2536109\/blooda_adv-2025-019064-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:23Z","timestamp":1786463003000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5325\/568865\/Real-world-treatment-patterns-of-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":42,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019064","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,31]]}}}